Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for persistent dyspnea after COVID-19 discharge
IRCT20200707048047N1Phase 2Completed
- Sponsor
- Islamic Azad University
- Start
- Jul 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and post-COVID syndrome comparing Colchicine with Placebo (2 arms). Primary endpoints: Persistent dyspnea, Pulmonary fibrosis and 1 more. Started Jul 2020; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)post-COVID syndrome
Beyond the preview
Go deeper on IRCT20200707048047N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200707048047N1.